Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...
Hims & Hers Health shares jumped some 20% to a record high on Wednesday following the announcement that it acquired lab ...
22hon MSN
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback